Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim - LARVOL DELTA

Practical Considerations for the use of IL-23p19 Inhibitors in Inflammatory Bowel Disease: How to Choose Between Them and Why it Matters? (PubMed, J Crohns Colitis) - "Three such agents, Risankizumab, Mirikizumab and Guselkumab, have now been approved in CD and UC. Its use in combination with other advanced therapies in selected patients is being explored to enhance therapeutic efficacy and improve long-term outcomes. Further real-world studies are needed to assess its effectiveness and benefits in complex disease phenotypes, including perianal fistulizing Crohn's disease."

Journal • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Psoriasis • Ulcerative Colitis • IL23A

Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. (PubMed, Aliment Pharmacol Ther) - "Novel IL-23 inhibitors (such as mirikizumab, risankizumab and guselkumab) and anti-TNFs (such as infliximab and adalimumab) ranked high in the induction of clinical and endoscopic remission. This highlights the potential of novel advanced therapies for CD."

Journal • Retrospective data • Review • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

The impact of biological interventions on health-related quality of life in adults with Crohn's disease: a systematic review with meta-analysis. (PubMed, EClinicalMedicine) - "A clinically meaningful IBDQ score improvement was observed for infliximab (mean difference (MD) of 16.09 (95% CI: -0.13 to 32.31; 4 studies; 1162 participants, very low-certainty evidence)) and upadacitinib (MD 20.65, 95% CI 7.04-34.25; I2 = 42.8%, P = 0.17; 3 studies; 1523 participants; high-certainty evidence). No significant IBDQ improvement was observed for adalimumab, certolizumab pegol, ustekinumab, or natalizumab compared to placebo (low-to high-certainty evidence). Due to considerable heterogeneity, data on vedolizumab and risankizumab could not be pooled...There is a large unmet need to investigate the association between clinical outcomes and HRQoL outcomes more thoroughly. None."

HEOR • Journal • Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

AbbVie lifts profit forecast on strong demand for newer immunology drugs (Reuters) - "The company is pushing Skyrizi and Rinvoq to counter the drop in sales of arthritis treatment Humira, as the once-bestselling drug faces competition from several cheaper biosimilars that began hitting the U.S. market in 2023...Skyrizi recorded quarterly sales of $4.42 billion, beating analysts' average estimate of $4 billion, while Rinvoq sales of $2.03 billion surpassed estimates of $1.97 billion, according to data compiled by LSEG...Global sales of Humira, once the world's best-selling drug, came in at $1.18 billion in the second quarter, missing estimates of $1.45 billion."

Sales • Asthma • Atopic Dermatitis • Hidradenitis Suppurativa • Inflammatory Bowel Disease • Ocular Inflammation • Pain • Psoriasis • Rheumatoid Arthritis

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. (PubMed, Am J Clin Dermatol) - P3 | "Long-term risankizumab was well tolerated and demonstrated high and durable efficacy through 6 years of continuous treatment."

Journal • P3 data • Dermatology • Immunology • Inflammation • Psoriasis

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis. (PubMed, Dermatol Ther (Heidelb)) - "IL-17 inhibitors, followed by IL-23 inhibitors, have the most rapid TOA among PsO biologics evaluated; any differences in onset of action between specific agents within the same drug class are not statistically or clinically significant. These analyses will allow clinicians to make more informed treatment decisions for their patients."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL12A • IL17A • IL23A

Risankizumab, but not Guselkumab, Promotes Extensive Vitiligo Repigmentation in a Patient with Psoriasis Vulgaris: A Case Report (EADV 2025) - No abstract available

Case report • Clinical • Dermatology • Immunology • Psoriasis • Vitiligo

Quantifying the Role of Specialty Medications in Medicare Part D Expenditures in Dermatology. (PubMed, JAMA Dermatol) - "New therapies approved after 2013 (Otezla, Cosentyx, Taltz, Dupixent, Tremfya, Skyrizi, and Odomzo) accounted for 69.5% of all spending growth. Prescription rates increased more slowly for older specialty drugs (Humira, Enbrel, Stelara, and Erivedge), but their prices increased more (9.2% annually) than prices for newer agents...While the price of the average dermatologic medication has increased rapidly, this primarily reflects increased prescribing of newly introduced specialty drugs. While these therapies expand treatment options, their rising share of costs highlights the need for policies that balance innovation, access, and affordability."

Journal • Medicare • Reimbursement • US reimbursement • Dermatology

Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis. (PubMed, Expert Opin Biol Ther) - "It discusses both ustekinumab, a nonselective IL-12/23p40 blocker, and selective IL-23p19 inhibitors (i.e. mirikizumab, guselkumab, and risankizumab), covering their mechanisms of action, clinical efficacy, and safety profiles from registrative and post-marketing studies. Oral agents represent an exciting frontier, potentially improving patient adherence and accessibility. Direct comparative trials are needed to refine therapeutic positioning in personalized treatment algorithms."

Clinical data • Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A • IL23A • TYK2

Real-World Efficacy and Safety of Risankizumab in Psoriasis: Insights After Failure of Ustekinumab and Other Biologics (EADV 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Psoriasis

Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). (PubMed, Dermatol Ther (Heidelb)) - "This study provides valuable real-world data on the long-term effectiveness and durability of biologic treatments for PsO, emphasizing the advantages of anti-IL-17A biologics, particularly IXE, in achieving and maintaining therapeutic responses. These findings support dermatologists in making informed decisions regarding PsO treatment strategies."

HEOR • Journal • Dermatology • Immunology • Oncology • Psoriasis • IL12A • IL17A • IL23A

Real-World Effectiveness and Safety of Risankizumab in Psoriasis: A Comprehensive Analysis from the Saudi Arabia Psoriasis Registry (PSORSA). (PubMed, Dermatol Ther (Heidelb)) - "This study represents the first real-world assessment of risankizumab for moderate-to-severe psoriasis in Saudi Arabia. The findings demonstrate that risankizumab is an effective and well-tolerated treatment for moderate-to-severe psoriasis in this Saudi Arabian cohort. However, future studies should explore long-term safety outcomes and the comparative effectiveness of risankizumab and emerging biologics in diverse patient populations."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

Real-world 52-week effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a prospective single-centre cohort (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Time to Treatment Change in Patients Receiving Risankizumab vs Other Biologic Therapies Over 3 years: Interim Analysis of the VALUE Study (EADV 2025) - No abstract available

Clinical • Dermatology • Dermatopathology • Immunology • Psoriasis

Reduction of genital psoriasis symptoms in male and female patients treated with risankizumab – interim results from a real-world study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

3-year data on effectiveness and quality of life in bio-naïve patients treated with risankizumab or other biologics in clinical practice – German cohort of the VALUE study (EADV 2025) - No abstract available

Clinical • HEOR • Dermatology • Dermatopathology • Immunology • Psoriasis

Real-World Treatment Switch Rates for Risankizumab Compared With Deucravacitinib in Patients With Psoriasis (EADV 2025) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Subacute Annular Pustular Psoriasis with flexural accentuation: Dramatic response to Risankizumab (EADV 2025) - No abstract available

Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Real-World Skin Clearance Target Achievement With Persistent Risankizumab Use in Patients With Moderate-Severe Psoriasis From the CorEvitas Psoriasis Registry (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Real-World Effectiveness of Risankizumab Compared to Other Biologics Over 3 Years: Interim Analysis of the VALUE Study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Dermatopathology • Immunology • Psoriasis

Safety and Efficacy of Risankizumab in Genital and Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16 (EADV 2025) - No abstract available

Clinical • P4 data • Dermatology • Immunology • Psoriasis

A randomized, double-blind, placebo-controlled Phase 3 clinical trial of sonelokimab—including a risankizumab reference arm—in patients with active psoriatic arthritis and previous inadequate response or intolerance to biologic TNFi therapy (IZAR-2): Study design and rationale (EADV 2025) - No abstract available

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Head-to-head study of bimekizumab, an IL-17A/IL-17F inhibitor, and risankizumab, an IL-23 inhibitor, in patients with active psoriatic arthritis: Study design and rationale of BE BOLD, a phase 3b, randomised, parallel-group study (EADV 2025) - No abstract available

Clinical • Head-to-Head • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A

Drug survival, effectiveness, and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years. (PubMed, Clin Exp Dermatol) - "Our study confirms the good effectiveness and favorable safety of risankizumab in a real-world setting for up to four years."

Clinical • Journal • Dermatology • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Treatment of hidradenitis suppurativa with Risankizumab in patients with Crohn's disease (EADV 2025) - No abstract available

Clinical • Crohn's disease • Dermatology • Gastroenterology • Hidradenitis Suppurativa • Immunology • Inflammatory Bowel Disease